Curium is said to near about $7 billion acquisition of Lanthius

Curium, a leading provider of specialty pharmaceuticals, is reportedly close to finalizing a $7 billion acquisition of Lanthius, a company known for its expertise in radiopharmaceuticals and advanced nuclear medicine[1]. The potential deal, if completed, would represent one of the largest transactions in the sector in recent years and is expected to significantly expand Curium’s product portfolio and market reach.

According to sources familiar with the matter, the acquisition is being driven by strategic goals to consolidate the radiopharmaceutical supply chain and enhance capabilities in the production of medical isotopes[2]. The companies have not officially confirmed the deal, but industry analysts suggest that regulatory approvals and due diligence are nearing completion.

The transaction would be financed through a combination of cash reserves and new debt, with [no immediate indication of equity issuance][3]. Investors are closely watching the development, as the deal could reshape the competitive landscape in the nuclear medicine industry.